Mobia Medical began trading on Nasdaq under ticker MOBI after completing an IPO priced at $15 per share, raising about $150 million. The company sold 10 million shares at the midpoint of its $14–$16 range, and shares closed at $11.75 on the first day of trading, down 21.7% from the offering price. Mobia’s therapy, Vivistim Paired VNS, is a vagus-nerve stimulation approach intended to improve upper-limb function in chronic ischemic stroke survivors with moderate to severe impairments. The IPO provides fresh capital to support commercialization and further clinical development tied to the device-based neuromodulation strategy. The debut highlights continued market access for med-tech and neurostimulation plays, even as first-day trading volatility signals investor caution on early commercial momentum.